Founders Financial Alliance LLC Sells 6,896 Shares of CVS Health Co. (NYSE:CVS)

Founders Financial Alliance LLC lessened its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 40.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,191 shares of the pharmacy operator's stock after selling 6,896 shares during the quarter. Founders Financial Alliance LLC's holdings in CVS Health were worth $457,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC boosted its stake in CVS Health by 28.7% in the 3rd quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator's stock worth $2,951,000 after buying an additional 10,465 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock worth $90,200,000 after acquiring an additional 66,244 shares during the last quarter. Sompo Asset Management Co. Ltd. grew its holdings in CVS Health by 8.4% in the third quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator's stock valued at $8,459,000 after purchasing an additional 10,453 shares during the period. Hall Laurie J Trustee increased its position in CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock worth $517,000 after purchasing an additional 11,468 shares during the last quarter. Finally, B&D White Capital Company LLC acquired a new position in shares of CVS Health in the 4th quarter valued at $417,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

CVS Health Price Performance

Shares of NYSE:CVS traded up $0.30 during midday trading on Wednesday, hitting $65.28. The stock had a trading volume of 3,983,000 shares, compared to its average volume of 11,611,090. The company's 50-day moving average price is $57.24 and its 200-day moving average price is $56.83. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $82.31 billion, a P/E ratio of 17.85, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities research analysts predict that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.07%. CVS Health's payout ratio is presently 72.68%.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael F. Mahoney purchased 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares in the company, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company's stock.

Wall Street Analyst Weigh In

CVS has been the topic of several recent research reports. Barclays lifted their target price on shares of CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded CVS Health from a "hold" rating to a "buy" rating and set a $66.00 target price on the stock in a report on Tuesday, December 3rd. TD Cowen lifted their price objective on shares of CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a research note on Monday, November 25th. Evercore ISI lifted their price target on shares of CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research note on Monday, January 27th. Finally, Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, CVS Health has a consensus rating of "Moderate Buy" and a consensus target price of $69.83.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.